Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2012-06-27 Regulatory Filings
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is reporting an event dated June 27, 2012, specifically the dosing of the first patient in a clinical study and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is short (2300 characters) and primarily serves as an announcement of a corporate event and press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2012-06-27 English
4 Filing
Director's Dealing
2012-06-15 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content describes an amendment to the Articles of Incorporation to delete provisions related to a previously converted preferred stock series. There are no financial statements or detailed financial data included, only a description of a corporate governance change and an attached amendment document. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Interim Report, or Capital Update. The document length is short and it is not a report publication announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2012-06-14 English
S-3 Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale, including common stock, preferred stock, warrants, debt securities, and units, with a total offering amount of up to $75,000,000. The document includes detailed information about the securities, the company, risk factors, use of proceeds, and plan of distribution. This type of filing is related to capital raising and financing activities rather than financial reporting, management changes, or other categories. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not merely an announcement of a report. Hence, the classification is CAP with high confidence.
2012-06-14 English
4 Filing
Director's Dealing
2012-06-05 English
4 Filing
Director's Dealing
2012-06-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.